Pharmacokinetics and tolerance of weekly OXYGENT CA infusions in the dog.
This study determined the OXYGENT CA (90% w/v perflubron emulsion, Alliance Pharmaceutical Corporation) dose necessary to achieve a 3-4% fluorocrit, and the tolerance of this dose administered once per week for four weeks to dogs. This study simulated OXYGENT CA use as a radiosensitizing agent. Six adult dogs were administered 6 ml/kg OXYGENT CA once per week for 4 weeks. Blood samples were collected following infusion, until fluorocrits were < or = 0.5%. One week after the fourth infusion, three dogs were necropsied. Liver biopsies were obtained from the remaining three dogs which were monitored 12 additional weeks. All dogs achieved fluorocrits > 3.0% (3.5-5.1%) with the 6 ml/kg dose. A 3 ml/kg dose did not provide a fluorocrit > 3.0%. Serum bilirubin concentrations were elevated at 24-hour sampling times and declined within 72 hours. Elevations in ALT, SAP, and bile acids were noted. Splenic and hepatic microvasculature fibrosis occurred in the long-term study dogs. Thrombocytopenia occurred in 5/6 dogs, necessitating exclusions of one dog from 2 infusions. However, 3/5 thrombocytopenic dogs had titers for Ehrlichia sp., which elicits thrombocytopenia. Therefore, we cannot conclude the effect of OXYGENT CA on platelets.